tbuckley/cabot-search huggingface dataset:
Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy
Authors: Massimo Massaia, Paolo Borrione, Silvano Battaglio, Sara Mariani, Eloise Beggiato, Patrizia Napoli, Claudia Voena, Alberto Bianchi, Marta Coscia, Barbara Besostri, Silvia Peola, Thomas Stiefel, Jos Even, Domenico Novero, Mario Boccadoro, Alessandro Pileri
Journal: Blood (1999)
Effect of alcohol consumption on state anxiety changes in male and female nonalcoholics
Authors: P E Logue, W D Gentry, M Linnoila, C W Erwin
Journal: American Journal of Psychiatry (1978)

Ten male and 10 female nonalcoholic college students were given drinks having alcohol levels of 0, 0.5, 0.8, and 1.2 g/kg. They were then given four complex psychomotor tests, immediately before and after which they were given the Spielberger State Anxiety Inventory, and asked to rate their performance on a five-point scale. Mean anxiety change scores were -.90, .75, 4.75, and 5.55 for the four alcohol doses, respectively. There was no significant correlation between anxiety change and actual performance on the visual vigilance task, but for males there was a significant correlation between anxiety change and perceived level of impairment.
Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC)
Authors: M. D. Vincent, C. Butts, L. Seymour, K. Ding, B. Graham, P. Twumasi-Ankrah, D. Gandara, J. Schiller, M. Green, F. Shepherd
Journal: Journal of Clinical Oncology (2009)

7501 Background: JBR.10 was one of a number of phase III trials that established adjuvant cisplatin based chemotherapy as a recommended treatment in completely resected NSCLC . Long-term follow-up of these trials is important to document persistent benefit and potential late toxicities of adjuvant therapy. We report the updated survival data for JBR.10 with more than 9 years median follow up. Methods: Patients with completely resected stage IB (T2N0) or II (T1–2N1) NSCLC were randomized to receive 4 cycles of vinorelbine/cisplatin or observation.. Kaplan-Meier curves were generated for overall (OS) and disease specific survival (DSS). Log-rank test was used to compare survival distribution and to test cause specific hazard. For the competing risk analysis, the Gray test was used to test the difference in cause specific incidences. All efficacy analyses were done on an ITT basis. Results: 482 patients were randomized. Data cut-off for this update was July 2008. Median follow-up is 9.3 years (3.2–13.8 y). 12 patients were lost to follow up, a median 4.9 years from randomization (1.5–12 years). 271 deaths have occurred, 73% due to lung cancer or its treatment. Survival analysis continues to show a benefit for chemotherapy: HR .78 (CI .61-.99, p=.04). The benefit appears to be confined to N1 patients: median OS 6.8 y versus 3.6 y, HR .68 (CI .5-.92, p=.01). N0 patients did not appear to benefit: HR 1.03 (CI .7–1.52, p=.87). Chemotherapy significantly prolonged DSS, HR.73 (CI .55-.97, p=.03) Competing risk analysis showed observation to be associated with significantly higher risk of death from lung cancer (p=.02) with no difference in incidences of death from other causes between arms (p=.62). Conclusions: Prolonged follow-up of patients in the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm. [Table: see text]
Conserved epigenetic changes in sporadic and HIV-associated high-grade B-cell lymphomas
Authors: T. Crook, P. Smith, N. Syed, J. Stebbing, B. Griffin, M. Bower, K. Naresh
Journal: Journal of Clinical Oncology (2007)

18540 Background: Transcriptional silencing represents a major mechanism of tumour suppressor gene inactivation in human tumours, including lymphoma. Here, we have compared patterns of aberrant methylation in sporadic and HIV-associated B cell lymphomas. Methods: We used methylation reversal/ micro-array analysis to seek novel genes subject to methylation-dependent transcriptional silencing in B cell lymphoma cell lines and primary B cell lymphomas from immune competent and HIV positive patients. Results: We describe the identification from these studies of a number of genes previously unreported as human tumour suppressors that are subject to transcriptional silencing in B lymphomas. Analysis of a subset of these genes, together with a panel of previously identified transcriptionally-silenced genes in primary B lymphomas, both sporadic and HIV-associated, revealed that patterns of aberrant methylation were highly conserved between the two patient groups. In contrast, we found no epigenetic changes in any of the analysed genes in EBV-immortalised B lymphoblastoid cell lines. Conclusions: These studies show that a similar subset of genes is subject to methylation-dependent transcriptional silencing in B lymphomas in sporadic and HIV-associated cases, implying that the same tumour suppressor pathways are inactivated and arguing that, at least epigenetically, these disorders are very similar disease entities. No significant financial relationships to disclose.
NHS phone triage system sends too many to emergency departments, study finds
Authors: Gareth Iacobucci
Journal: BMJ (2015)

Almost three quarters of patients sent to hospital emergency departments by an NHS 111 telephone triage centre went unnecessarily, a new study has found.

Researchers at the University of Cambridge analysed 1474 cases where GPs reviewed decisions taken by non-medical NHS 111 call handlers to send patients to emergency departments from a call centre in Cambridgeshire. The study, published in BMJ Open ,1 found that the GPs advised attendance at an emergency department in only 400 (27%) of these cases.

The GPs advised that in …
Dose-escalating study of yttrium 90 microspheres with capecitabine for intrahepatic cholangiocarcinoma or metastatic disease to the liver.
Authors: R. M. Hickey, M. F. Mulcahy, R. Lewandowski, R. Salem
Journal: Journal of Clinical Oncology (2010)

TPS216 Background: Radiosensitizing chemotherapy has been shown to improve outcomes compared to radiation alone for several gastrointestinal cancers. Delivery of internal radiation to primary and metastatic hepatic malignancies provides an opportunity to enhance radiation effects when used with radiosensitizing chemotherapy. Y90, integrated into nonbiodegradable microspheres, is a brachytherapy treatment option that can be administered by intra-arterial hepatic injection, delivering high radiation doses to tumors while sparing liver parenchyma that results in tumoricidal effects with minimal liver toxicity. Capecitabine is an oral, tumor-activated fluoropyrimidine that preferentially delivers 5-FU to tumor cells via thymidine phosphorylase (TP). As TP is up-regulated by radiotherapy, internal tumor radiation may increase preferential delivery of 5-FU to the tumor. This study will identify the maximally tolerated dose (MTD) of Y90 that can be administered with standard dose of capecitabine for the treatment of intrahepatic cholangiocarcinoma and/or intrahepatic liver metastases, characterize the toxicity of capecitabine and Y90, and determine time to tumor progression. Methods: Eligible patients have histologically confirmed intrahepatic cholangiocarcinoma or metastatic cancer confined to the liver that represents <50% of total liver volume. No more than two prior therapies for hepatic metastatic disease, no prior hepatic radiation and no prior intervention or compromise of the Ampulla of Vater are permitted. The proposed sample size ranges from 12 to 20 patients. Subjects will be treated with sequential cycles of capecitabine for 14 days of a 21-day cycle and receive an assigned dose of Y90 between days 1 and 7 of cycle two. Dose-limiting toxicity (DLT) will be determined up to 6 weeks from Y90 infusion. The primary endpoint will be to determine the maximum tolerated dose of Y90 with capecitabine. Secondary endpoints will include evaluation of overall and hepatic response. Hepatic response will be measured with cross-sectional imaging. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration MDS Nordion
Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients
Authors: Jian Ruan, Haiyan Zheng, Xiaodong Rong, Xiaomin Rong, Junyi Zhang, Weijia Fang, Peng Zhao, Rongcheng Luo
Journal: Molecular Cancer (2016)

Several studies have found that Cathepsin B (CTSB) is up-regulated in many tumor types and facilitates tumor progression. However, the role of CTSB in hepatocellular carcinoma (HCC) progression remains unclear. This study was aimed at investigating the expression and role of CTSB in HCC in a large set of samples and cell lines (MHCC-97H and MHCC-97 L), and evaluating the clinical and prognostic significance of CTSB protein in patients with HCC. The expression of CTSB was examined in HCC tissue and cell lines by Western-blotting, Real-time PCR, and immunohistochemical staining. Wound healing assay and invasion assay were used to verify the effect of CTSB on the migration and invasion ability of HCC cell lines. Tumor formation assay in nude mice was used to analyze the effect of CTSB on the tumorigenicity of HCC cell lines. The status of CTSB protein in carcinoma tissues is much higher than that in paracarcinoma tissues. The overall survival of the patients with high CTSB expression was significantly shorter than the low CTSB expression group. High CTSB expression was significantly correlated with advanced clinical staging, histological grade, and tumor recurrence. In vitro and in vivo experiments demonstrated that over-expression of CTSB in MHCC-97 L cells promoted cell invasion and tumor progression ability. Down-regulation of CTSB in MHCC-97H showed the opposite effects. These phenotypic changes caused by CTSB knockdown or over-expression correlated with expression of the matrix metallopeptidase MMP-9. Moreover, multivariate analysis suggested that CTSB expression might be an independent prognostic indicator for the survival of HCC patients after curative surgery. CTSB might be involved in the development and progression of HCC as an oncogene, and thereby may be a valuable prognostic marker for HCC patients.
Belsen Camp : a Preliminary Report.
Authors: W. R. F. Collis
Journal: BMJ (1945)

camp is separated into two distinct portions-Camps 1 and 2. Camp 1 is a hutted encampment housing approximately 22,000 females and 18,000 males. Camp 2 consists of a series of brick buildings and houses approximately 27,000 males. The inhabitants of these camps are of mixed nationalities, with Russians and Poles predominating. Czechs, Belgians, French, and Italians are also present. CONDITIONS PREVAILING
Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: Are clinicians responding appropriately?
Authors: M. L. Telli, G. Yoon, D. Kao, K. Matsuda, R. M. Witteles
Journal: Journal of Clinical Oncology (2009)

9527 Background: Cancer survivors treated with anthracyclines and/or trastuzumab are at risk for cardiotoxicity. Left ventricular (LV) systolic dysfunction (symptomatic or asymptomatic) represents a Class I indication for therapy with beta-blockers and angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) according to American College of Cardiology/American Heart Association heart failure guidelines. We designed this study to examine treatment practices for patients with cancer therapy-associated LV dysfunction, and the real-world adoption of treatment guidelines. Methods: After IRB approval, we identified all patients who received anthracycline and/or trastuzumab cancer therapy at Stanford University from October 1, 2005 to October 31, 2007 using an institutional pharmacy database. Out of 6,530 total cycles of chemotherapy administered, we identified all unique patients who had at least one echocardiogram performed before and after the start of chemotherapy using an institutional echocardiography database. Details of the chemotherapy regimen, cardiac risk factors, cardiac imaging results, concomitant medications, and referrals/consultations were examined for these patients. Results: A total of 88 patients met inclusion criteria. Ninety-two percent were treated with anthracyclines, 25% with trastuzumab in combination with anthracyclines, and 8% with trastuzumab alone. Mean baseline ejection fraction (EF) was 60%, with 13% of patients having a baseline EF below normal. A total of 41% had LV dysfunction (EF less than 55%) during or after cancer therapy. Of these patients, 56% received beta-blocker therapy, 47% received ACE-I or ARB therapy, and 50% were referred for cardiology consultation. Of the patients with asymptomatic LV dysfunction (75% of the LV dysfunction cohort), 41% received beta-blocker therapy, 33% received ACE-I or ARB therapy, and 37% received cardiology consultation. Conclusions: In real-world clinical practice, many cancer survivors with cardiotoxicity are not adequately evaluated and treated from a cardiovascular standpoint. Multidisciplinary collaboration between oncologists and cardiologists is needed to improve the quality of care for these patients. No significant financial relationships to disclose.
Allogeneic hematopoietic cell transplant for multiple myeloma: Comparative results of planned therapy versus salvage therapy
Authors: L. Shune, D. J. Weisdorf, B. McClune, L. Ma, L. J. Burns, J. Miller, A. Slungaard, M. Arora
Journal: Journal of Clinical Oncology (2009)

7035 Background: Despite advances in therapy for multiple myeloma, the disease remains incurable using chemotherapy or immune-modulating agents alone. Several newer hematopoietic cell transplant (HCT) strategies including tandem HCT, and non- myeloablative (NMA) regimens have reported encouraging results. However, the appropriate timing for utilizing these strategies is not clear. Methods: We report outcomes in 51 patients with multiple myeloma who received an allogeneic HCT; either as salvage therapy (after failing a prior autologous HCT), n= 15 or as planned therapy, n= 36, between the years 1996 and 2008 at University of Minnesota. Results: Patients in salvage therapy group were significantly older than in planned therapy group (median age 58 versus 49 years) and had a longer interval from diagnosis to transplant (median 47 versus 10 months). Forty four patients received a HCT from a HLA-identical sibling. Five received umbilical cord blood (four in salvage therapy, one in planned therapy group) and two received unrelated donor HCT (one in each group). Thirteen patients in planned therapy group underwent a tandem transplant (planned autologous followed by NMA sibling HCT). All patients in salvage therapy group, and 50% in planned therapy group received NMA HCT. Patients in salvage therapy group were more heavily pre-treated, all having failed a prior autologous HCT. Complete response was seen in 34% versus 47% of recipients in the two groups, respectively. After a median follow-up of 24 and 41 months, similar relapse was seen, but transplant related mortality (TRM) was significantly higher in salvage therapy group, leading to significantly lower two year survival and disease free survival (DFS) in salvage group. Conclusions: Good overall survival and low transplant related mortality was seen in patients undergoing a planned allogeneic transplant. In heavily pre-treated patients, receiving allogeneic HCT as salvage therapy, despite lower relapse, the high TRM led to lower survival. [Table: see text] No significant financial relationships to disclose.
Quality Assessment of the Ethics Consultation Service at the Organizational Level: Accrediting Ethics Consultation Services
Authors: Kenneth A. Berkowitz, Aviva L. Katz, Kathleen E. Powderly, Jeffrey P. Spike
Journal: The American Journal of Bioethics (2016)

"Quality Assessment of the Ethics Consultation Service at the Organizational Level: Accrediting Ethics Consultation Services." The American Journal of Bioethics, 16(3), pp. 42–44
Comparison of Young Clinical Investigators’ Accuracy and Reproducibility When Measuring Pulmonary and Skin Surface Nodules Using a Circumferential Measurement Versus a Standard Caliper Measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop
Authors: Wayne L. Monsky, David K. Heddens, Gary M. Clark, Daniel D. Von Hoff, Charles A. Coltman, Robert T. Dorr, David S. Alberts
Journal: Journal of Clinical Oncology (2000)

The clinical investigator must understand that errors in measuring tumors can greatly affect such clinical-trial end points as tumor response. We performed a prospective, controlled study of tumor measurements that compared circumferential measurements made with a loop planimeter with linear measurements made with a standard caliper.Using a cross-over design, 76 clinical oncology fellows/junior oncology faculty members attending a Methods in Clinical Cancer Research Workshop sponsored by the American Association for Cancer Research and the American Society of Clinical Oncology measured five pulmonary nodule phantoms that ranged in size from 1.76 to 13.21 cm(2) and five surface nodule phantoms with sizes ranging from 2.3 to 12.9 cm(2). To perform these measurements, they used both a loop planimeter and a caliper. Forty-two and 40 participants repeated measurements 3 days later on pulmonary and surface nodules. Accuracy, reproducibility, and time efficiency were evaluated.The linear caliper measurements overestimated pulmonary nodule and surface nodule size by a median of 37% and 23%, respectively. Circumferential loop planimeter measurements overestimated pulmonary nodule size and surface nodule size by a median of 8% and 17%, respectively. Interobserver reproducibility for the planimeter was greater than that for the caliper, as evidenced by thinner measurement interquartile ranges. Furthermore, intraobserver reproducibility was higher for the planimeter, with its variability being only 31.4% and 25.5% as large as that of the caliper when measuring the pulmonary and surface nodules, respectively.Circumferential measurements provide better accuracy, reproducibility, and speed in measuring both pulmonary and surface nodules than do perpendicular diameters.
Racial Differences in Breast Cancer Patients&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: H E Ownby, J Frederick, J Russo, S C Brooks, G M Swanson, G H Heppner, M J Brennan
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Racial Differences in Breast Cancer Patients Get access Helen E. Ownby, Helen E. Ownby Search for other works by this author on: Oxford Academic PubMed Google Scholar James Frederick, James Frederick Search for other works by this author on: Oxford Academic PubMed Google Scholar Jose Russo, Jose Russo Search for other works by this author on: Oxford Academic PubMed Google Scholar S. C. Brooks, S. C. Brooks Search for other works by this author on: Oxford Academic PubMed Google Scholar G. Marie Swanson, G. Marie Swanson Search for other works by this author on: Oxford Academic PubMed Google Scholar Gloria H. Heppner, Gloria H. Heppner Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael J. Brennan, Michael J. Brennan Search for other works by this author on: Oxford Academic PubMed Google Scholar the Breast Cancer Prognostic Study Associates the Breast Cancer Prognostic Study Associates Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 75, Issue 1, July 1985, Pages 55–60, https://doi.org/10.1093/jnci/75.1.55 Published: 01 July 1985 Article history Received: 29 October 1984 Accepted: 05 March 1985 Published: 01 July 1985
Impact of mobile mammography among the medically underserved.
Authors: J. Y. Lee, K. Enoch, R. Gibson, C. Stewart, R. Fincher, K. Bland, M. Thompson, V. S. Klimberg, R. S. Henry-Tillman
Journal: Journal of Clinical Oncology (2010)

e12027 Background: Mammography has been established as the primary screening tool for breast cancer. The decline in the number of FDA-approved stationary mammography units has resulted in a significant proportion of counties in rural states without a single unit. Mobile mammography has the potential to enhance access to mammography among the medical underserved. This report describes the use of a mobile modular mammography unit in Arkansas. Methods: From 2003-2007, a modular mammography unit traveled to 28 counties, 21 of which lacked a stationary unit. The number of mammograms performed and their outcomes were collected at each visit. Demographic information, health insurance status and previous mammography use were captured. Results: The modular unit made 179 day-long visits and performed 2427 mammograms for an average of 13.6 mammograms per visit. Of the 2427 mammograms performed, 1619 (67%) were normal and 808 (33%) required additional views. Ninety-four patients (4%) required biopsies and 4 (0.16%) were diagnosed with ductal carcinoma in situ (DCIS). One-third of participants were African-American; 2% were Hispanic; and the remainder were Caucasian. Most had some form of health insurance: private (24%), Medicare (37%), Medicaid (7%), or Breast Care (30%), a state-run program to provide mammograms to low-income women. The average age was 57 years and most (77%) had previously had a mammogram. Counties served by the unit were medically underserved with 57 physicians per 100,000 population in comparison to a nationwide rate of 297 per 100,000, and 75% lived in rural areas. Conclusions: The modular unit enhanced access to mammography among those whose ability to obtain a mammogram was limited by geographic location or socioeconomic factors. The rate of detection of DCIS was 1.60 per 100,000 women screened, a rate slightly higher than the age-adjusted breast cancer incidence rate in Arkansas of 1.17 per 100,000. Early detection by mobile mammography has the potential to reduce the morbidity, mortality and treatment cost among the medically underserved. No significant financial relationships to disclose.
Abstract 15448: Both Aggressive Ablation and Volume Management Reduce the Need for Repeat Alcohol Septal Ablations in Patients With Hypertrophic Cardiomyopathy
Authors: Robert H Yoe, Paul Maddux, Oliver W Horne, Monique K Sandhu, Frederick Funke, Chetan A Patel, Rodolfo R Machado, Bethany J Wolf, Anbukarasi Maran, Valerian Fernandes, Thomas Todoran, Daniel H Steinberg, Eric Powers, Christopher D Nielsen
Journal: Circulation (2013)